Preventive drugs for Huntington's disease: A choice-based conjoint survey of patient preferences.

ABSTRACT:

Introduction

This research examined the perspective of the Huntington's disease (HD) community regarding the use of predictive biomarkers as endpoints for regulatory approval of therapeutics to prevent or delay the onset of clinical HD in asymptomatic mutation carriers.

Methods

An online, choice-based conjoint survey was shared with HD community members including untested at-risk individuals, presymptomatic mutation carriers, and symptomatic individuals. Across 15 scenarios, participants chose among two proposed therapies with differing degrees of biomarker improvement and side effects or a third option of no treatment.

Results

Two hundred and thirty-eight responses were received. Attributes reflecting biomarker efficacy (e.g., prevention of brain atrophy on magnetic

SUBMITTER: Parrish MC 

PROVIDER: S-EPMC9003635 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature